Cargando…
Remicade(®) (infliximab): 20 years of contributions to science and medicine
On August 24, 1998, Remicade(®) (infliximab), the first tumor necrosis factor-α (TNF) inhibitor, received its initial marketing approval from the US Food and Drug Administration for the treatment of Crohn’s disease. Subsequently, Remicade was approved in another five adult and two pediatric indicati...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679695/ https://www.ncbi.nlm.nih.gov/pubmed/31440029 http://dx.doi.org/10.2147/BTT.S207246 |